, a provider of medical affairs and innovation management solutions, announced a strategic partnership with clinical data company WideTrial to facilitate greater access to investigational medicines for physicians and patients dealing with COVID-19 worldwide.
	
	The project’s objective is to establish a single centralized hub for access to potentially effective COVID-19 therapeutics through established Expanded Access (EA) regulations. While pharma manufacturers are not enforced to allow EA access to their investigational drugs, the hub is designed to handle demand if EAP are granted. The new platform is designed to allow interested healthcare providers (including non-traditional trial sites, community hospitals, and clinics) to sign up online to participate in the EAPs.